Inflammatory proteins in patients with obstructive sleep apnea with and without daytime sleepiness

Sleep and Breathing

Volumn 11, Issue 3, 2007, Pages 177-185

  de la Peña Bravo, Mónica ^a   Serpero, Laura D ^b   Barceló, Antonia ^a   Barbé, Ferran ^c   Agustí, Alvar ^a   Gozal, David ^b,d  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b University of Louisville School of Medicine   (United States)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^d KCHRI   (United States)

Author keywords

Excessive daytime sleepiness; Inflammation; Oxidant stress; Sleep disordered breathing

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PADGEM PROTEIN; PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DAYTIME SOMNOLENCE; EPWORTH SLEEPINESS SCALE; HUMAN; INFLAMMATION; MALE; MEDIATOR; PATIENT REFERRAL; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SLEEP APNEA SYNDROME; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

COHORT STUDIES; DINOPROST; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; MIDDLE AGED; OXIDATIVE STRESS; OXYGEN; P-SELECTIN; POLYSOMNOGRAPHY; PROSPECTIVE STUDIES; REFERENCE VALUES; SLEEP APNEA, OBSTRUCTIVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548162405     PISSN: 15209512     EISSN: 15221709     Source Type: Journal    
DOI: 10.1007/s11325-007-0100-7     Document Type: Article

References (85)

1. Douglas NJ, Polo O (1994) Pathogenesis of obstructive sleep apnoea/ hypopnoea syndrome (Review) (34 refs). Lancet 344(8923):653-655
2. Young T, Palta M, Dempsey J et al (1993) The occurrence of sleep-disordered breathing among middle-aged adults (see comment). N Engl J Med 328(17):1230-1235
3. Carrera M, Barbe F, Sauleda J et al (1999) Patients with obstructive sleep apnea exhibit genioglossus dysfunction that is normalized after treatment with continuous positive airway pressure. Am J Respir Crit Care Med 159(6):1960-1966
4. Young TB (2004) Epidemiology of daytime sleepiness: Definitions, symptomatology, and prevalence. J Clin Psychiatry 65(Suppl 16):12-16
5. Findley LJ, Barth JT, Powers DC et al (1986) Cognitive impairment in patients with obstructive sleep apnea and associated hypoxemia. Chest 90(5):686-690
6. Aldrich MS (1989) Automobile accidents in patients with sleep disorders. Sleep 12(6):487-494
7. Findley LJ (1990) Automobile driving in sleep apnea. Prog Clin Biol Res 345:337-343
8. Beutler LE, Ware JC, Karacan I et al (1981) Differentiating psychological characteristics of patients with sleep apnea and narcolepsy. Sleep 4(1):39-47
9. Vgontzas AN, Bixler EO, Chrousos GP (2003) Metabolic disturbances in obesity versus sleep apnoea: The importance of visceral obesity and insulin resistance. J Intern Med 254(1):32-44
10. ICSD - Diagnostic Classification Committee, Thorpy MJ C, American sleep disorders Association (1990) International classification of sleep disorders: Diagnostic and coding manual. Rochester, Minnesota
11. Newman AB, Spiekerman CF, Enright P et al (2000) Daytime sleepiness predicts mortality and cardiovascular disease in older adults. The Cardiovascular Health Study Research Group. J Am Geriatr Soc 48(2):115-123
12. Barbe F, Mayoralas LR, Duran J et al (2001) Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. Ann Intern Med 134(11):1015-1023
13. Mastorakos G, Chrousos GP, Weber JS (1993) Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 77(6):1690-1694
14. Papanicolaou DA, Tsigos C, Oldfield EH et al (1996) Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: Does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab 81(6):2303-2306
15. Entzian P, Linnemann K, Schlaak M et al (1996) Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. Am J Respir Crit Care Med 153(3):1080-1086
16. Vgontzas AN, Papanicolaou DA, Bixler EO et al (1997) Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. J Clin Endocrinol Metab 82(5):1313-1316
17. Vgontzas AN, Papanicolaou DA, Bixler EO et al (2000) Sleep apnea and daytime sleepiness and fatigue: Relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 85(3):1151-1158
18. Vgontzas AN, Zoumakis E, Lin HM et al (2004) Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab 89(9):4409-4413
19. Yudkin JS, Kumari M, Humphries SE et al (2000) Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 148(2):209-214
20. Marin JM, Carrizo SJ, Vicente E et al (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. Lancet 365(9464):1046-1053
21. Nieto FJ, Young TB, Lind BK et al (2000) Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 283(14):1829-1836
22. Peker Y, Hedner J, Norum J et al (2002) Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 166(2):159-165
23. Peppard PE, Young T, Palta M et al (2000) Prospective study of the association between sleep-disordered breathing and hypertension (see comment). N Engl J Med 342(19):1378-1384
24. Shahar E, Whitney CW, Redline S et al (2001) Sleep-disordered breathing and cardiovascular disease: Cross-sectional results of the Sleep Heart Health Study (see comment). Am J Respir Crit Care Med 163(1):19-25
25. Dean RT, Wilcox I (1993) Possible atherogenic effects of hypoxia during obstructive sleep apnea. Sleep 16(8 Suppl):S15-S21
26. Hedner JA, WISCE (1994) Speculations on the interaction between vascular disease and obstructive sleep apnea. In: Dekker M (ed) Sleep and breathing. INC, New York
27. Lavie L (2003) Obstructive sleep apnoea syndrome - an oxidative stress disorder (comment) (Review) (130 refs). Sleep Med Rev 7(1):35-51
28. Schulz R, Mahmoudi S, Hattar K et al (2000) Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 162(2 Pt 1):566-570
29. Barcelo A, Miralles C, Barbe F et al (2000) Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 16(4):644-647
30. Awad JA, Morrow JD, Takahashi K et al (1993) Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J Biol Chem 268(6):4161-4169
31. Roberts LJ, Morrow JD (2000) Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28(4):505-513
32. Schwedhelm E, Maas R, Troost R et al (2003) Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet 42(5):437-459
33. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685-1695
34. Simonini A, Moscucci M, Muller DW et al (2000) IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation 101(13):1519-1526
35. Haught WH, Mansour M, Rothlein R et al (1996) Alterations in circulating intercellular adhesion molecule-1 and L-selectin: Further evidence for chronic inflammation in ischemic heart disease. Am Heart J 132(1 Pt 1):1-8
36. Ross R (1993) The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362(6423):801-809
37. Pober JS, Bevilacqua MP, Mendrick DL et al (1986) Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 136(5):1680-1687
38. Chin K, Nakamura T, Shimizu K et al (2000) Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 109(7):562-567
39. El Solh AA, Mador MJ, Sikka P et al (2002) Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 121(5):1541-1547
40. Blankenberg S, Barbaux S, Tiret L (2003) Adhesion molecules and atherosclerosis. Atherosclerosis 170(2):191-203
41. Blann AD, McCollum CN (1998) Increased soluble P-selectin in peripheral artery disease: A new marker for the progression of atherosclerosis. Thromb Haemost 80(6):1031-1032
42. Ridker PM, Buring JE, Rifai N (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103(4):491-495
43. Carskadon MA, Dement WC, Mitler MM et al (1986) Guidelines for the multiple sleep latency test (MSLT): A standard measure of sleepiness. Sleep 9(4):519-524
44. Johns MW (1991) A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 14(6):540-545
45. Benbadis SR, Mascha E, Perry MC et al (1999) Association between the Epworth sleepiness scale and the multiple sleep latency test in a clinical population. Ann Intern Med 130(4 Pt 1):289-292
46. Ohga E, Nagase T, Tomita T et al (1999) Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 87(1):10-14
47. Haddy N, Sass C, Droesch S et al (2003) IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: The STANISLAS cohort. Atherosclerosis 170(2):277-283
48. Rothlein R, Mainolfi EA, Czajkowski M et al (1991) A form of circulating ICAM-1 in human serum. J Immunol 147(11):3788-3793
49. Morisaki N, Saito I, Tamura K et al (1997) New indices of ischemic heart disease and aging: Studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease. Atherosclerosis 131(1):43-48
50. Ridker PM, Hennekens CH, Roitman-Johnson B et al (1998) Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351(9096):88-92
51. Zund G, Uezono S, Stahl GL et al (1997) Hypoxia enhances induction of endothelial ICAM-1: Role for metabolic acidosis and proteasomes. Am J Physiol 273(5 Pt 1):C1571-C1580
52. Blann AD, Steele C, McCollum CN (1997) The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb Res 85(5):433-438
53. Ponthieux A, Herbeth B, Droesch S et al (2004) Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: The Stanislas study. Atherosclerosis 172(2):299-308
54. Bokinsky G, Miller M, Ault K et al (1995) Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest 108(3):625-630
55. Eisensehr I, Ehrenberg BL, Noachtar S et al (1998) Platelet activation, epinephrine, and blood pressure in obstructive sleep apnea syndrome. Neurology 51(1):188-195
56. Geiser T, Buck F, Meyer BJ et al (2002) In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 69(3):229-234
57. Hui DS, Ko FW, Fok JP et al (2004) The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 125(5):1768-1775
58. Sanner BM, Konermann M, Tepel M et al (2000) Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 16(4):648-652
59. von Kanel R, Dimsdale JE (2003) Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 124(5):1956-1967
60. Robinson GV, Pepperell JC, Segal HC et al (2004) Circulating cardiovascular risk factors in obstructive sleep apnoea: Data from randomised controlled trials. Thorax 59(9):777-782
61. Olson LJ, Olson EJ, Somers VK (2004) Obstructive sleep apnea and platelet activation: Another potential link between sleep-disordered breathing and cardiovascular disease. Chest 126(2):339-341
62. Papanicolaou DA, Wilder RL, Manolagas SC et al (1998) The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128(2):127-137
63. Biasucci LM, Vitelli A, Liuzzo G et al (1996) Elevated levels of interleukin-6 in unstable angina. Circulation 94(5):874-877
64. Carpagnano GE, Kharitonov SA, Resta O et al (2002) Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 122(4):1162-1167
65. Yokoe T, Minoguchi K, Matsuo H et al (2003) Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107(8):1129-1134
66. Inoue Ki, Takano H, Yoshikawa T et al (2003) Interleukin-6, Obstructive Sleep Apnea, and Obesity. Chest 124(4):1621-162a
67. Teramoto S, Yamamoto H, Ouchi Y (2003) Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnea syndrome. Circulation 107(5):E40
68. Tauman R, Ivanenko A, O'Brien LM et al (2004) Plasma C-reactive protein levels among children with sleep-disordered breathing. Pediatrics 113(6):e564-e569
69. Bauer J, Hohagen F, Ebert T et al (1994) Interleukin-6 serum levels in healthy persons correspond to the sleep-wake cycle. Clin Investig 72(4):315
70. De Simoni MG, De Luigi A, Gemma L et al (1993) Modulation of systemic interleukin-6 induction by central interleukin-1. Am J Physiol Regul Integr Comp Physiol 265(4):R739-R742
71. Opp MR (2002) Cytokines and sleep promotion: A potential mechanism for disorders of excessive daytime sleepiness. In: Pack AI (ed) Sleep apnea: pathogenesis, diagnosis, and treatment. Dekker, New York, pp 327-352
72. Vgontzas AN, Papanicolaou DA, Bixler EO et al (1999) Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 84(8):2603-2607
73. Vgontzas AN, Zoumakis E, Bixler EO et al (2004) Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 89(5):2119-2126
74. Vgontzas AN, Papanicolaou DA, Bixler EO et al (1999) Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 84(8):2603-2607
75. Fang J, Wang Y, Krueger JM (1997) Mice lacking the TNF 55 kDa receptor fail to sleep more after TNFalpha treatment. J Neurosci 17(15):5949-5955
76. Takahashi S, Kapas L, Krueger JM (1996) A tumor necrosis factor (TNF) receptor fragment attenuates TNF-alpha- and muramyl dipeptide-induced sleep and fever in rabbits. J Sleep Res 5(2):106-114
77. Minoguchi K, Tazaki T, Yokoe T et al (2004) Elevated production of tumor necrosis factor-α by monocytes in patients with obstructive sleep apnea syndrome. Chest 126(5):1473-1479
78. Row BW, Liu R, Xu W et al (2003) Intermittent hypoxia is associated with oxidative stress and spatial learning deficits in the rat. Am J Respir Crit Care Med 167(11):1548-1553
79. Zhan G, Serrano F, Fenik P et al (2005) NADPH oxidase mediates hypersomnolence and brain oxidative injury in a murine model of sleep apnea. Am J Respir Crit Care Med 172(7):921-929
80. Yamauchi M, Nakano H, Maekawa J et al (2005) Oxidative stress in obstructive sleep apnea. Chest 127(5):1674-1679
81. Morrow JD, Hill KE, Burk RF et al (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 87(23):9383-9387
82. Janssen LJ (2000) Isoprostanes: Generation, pharmacology, and roles in free-radical-mediated effects in the lung. Pulm Pharmacol Ther 13(4):149-155
83. Dworski D, Jackson L, Roberts L et al (2001) Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8- iso -PGF2). Clin Exp Allergy 31(3):387
84. Pratico D, Basili S, Vieri M et al (1998) Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med 158(6):1709-1714
85. Montuschi P, Ciabattoni G, Paredi P et al (1998) 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 158(5 Pt 1):1524-1527